|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.690 HKD | +0.60% |
|
-2.90% | -20.64% |
| 06-18 | CSPC Pharma's Tumor Drug Gets Trial Nod from US FDA | MT |
| 06-18 | CSPC Pharma Unit's Marketing Application for Anti-Inflammatory Drug Accepted in China | MT |
Company Valuation: CSPC Pharmaceutical Group Limited
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 100,932 | 97,707 | 86,022 | 55,169 | 96,380 | 76,487 | - | - |
| Change | - | -3.19% | -11.96% | -35.87% | 74.7% | -20.64% | - | - |
| Enterprise Value (EV) 1 | 89,633 | 86,241 | 72,284 | 46,931 | 86,710 | 65,436 | 63,151 | 60,033 |
| Change | - | -3.79% | -16.18% | -35.07% | 84.76% | -24.53% | -3.49% | -4.94% |
| P/E | 14.7x | 14.1x | 13.5x | 12.1x | 21.8x | 9.32x | 10.9x | 9.93x |
| PBR | 3.17x | 2.86x | 2.39x | 1.62x | 2.56x | 1.79x | 1.64x | 1.48x |
| PEG | - | 14.13x | -1.73x | -0.5x | -9.88x | 0.1x | -0.8x | 1.06x |
| Capitalization / Revenue | 2.94x | 2.77x | 2.52x | 1.78x | 3.26x | 2.15x | 2.18x | 2.03x |
| EV / Revenue | 2.61x | 2.44x | 2.12x | 1.51x | 2.94x | 1.84x | 1.8x | 1.6x |
| EV / EBITDA | 9.5x | 9.43x | 8.39x | 6.22x | 12.1x | 4.99x | 6.39x | 5.68x |
| EV / EBIT | 10.7x | 10.8x | 9.77x | 7.68x | 15.6x | 7.03x | 8.22x | 7.36x |
| EV / FCF | 23.7x | 14.1x | 26.2x | 17.5x | 19.5x | 7.96x | 9x | 6.27x |
| FCF Yield | 4.22% | 7.11% | 3.82% | 5.71% | 5.12% | 12.6% | 11.1% | 16% |
| Dividend per Share 2 | 0.18 | 0.21 | 0.28 | 0.26 | 0.29 | 0.3591 | 0.3656 | 0.3823 |
| Rate of return | 2.13% | 2.56% | 3.86% | 5.44% | 3.44% | 5.37% | 5.47% | 5.71% |
| EPS 2 | 0.5773 | 0.5831 | 0.5376 | 0.3946 | 0.3859 | 0.7181 | 0.6159 | 0.6739 |
| Distribution rate | 31.2% | 36% | 52.1% | 65.9% | 75.2% | 50% | 59.4% | 56.7% |
| Net sales 1 | 34,309 | 35,292 | 34,175 | 31,046 | 29,533 | 35,562 | 35,135 | 37,621 |
| EBITDA 1 | 9,431 | 9,148 | 8,615 | 7,547 | 7,168 | 13,116 | 9,883 | 10,578 |
| EBIT 1 | 8,366 | 7,952 | 7,400 | 6,113 | 5,564 | 9,309 | 7,687 | 8,151 |
| Net income 1 | 6,901 | 6,949 | 6,382 | 4,632 | 4,409 | 7,903 | 6,894 | 7,534 |
| Net Debt 1 | -11,298 | -11,467 | -13,738 | -8,238 | -9,670 | -11,051 | -13,336 | -16,454 |
| Reference price 2 | 8.470 | 8.200 | 7.260 | 4.780 | 8.430 | 6.690 | 6.690 | 6.690 |
| Nbr of stocks (in thousands) | 11,916,370 | 11,915,520 | 11,848,756 | 11,541,665 | 11,433,025 | 11,433,025 | - | - |
| Announcement Date | 22/03/22 | 22/03/23 | 20/03/24 | 28/03/25 | 25/03/26 | - | - | - |
1HKD in Million2HKD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
| 9.32x | 1.84x | 4.99x | 5.37% | 9.75B | ||
| 35.2x | 12.84x | 26.1x | 0.57% | 1,077B | ||
| 27.22x | 6.26x | 17.02x | 2.1% | 613B | ||
| 32.17x | 7.47x | 15.29x | 2.73% | 448B | ||
| 17.9x | 4.45x | 10.94x | 2.98% | 332B | ||
| 23.72x | 4.94x | 14x | 1.76% | 293B | ||
| 21.69x | 5.59x | 13.51x | 2.83% | 286B | ||
| 14.19x | 5.21x | 10.72x | 3.54% | 215B | ||
| 23.3x | 6.21x | 10.84x | 2.81% | 193B | ||
| -45.82x | 5.53x | 30.47x | 2.54% | 159B | ||
| Average | 15.89x | 6.03x | 15.39x | 2.72% | 362.58B | |
| Weighted average by Cap. | 24.40x | 7.93x | 18.28x | 1.98% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- 1093 Stock
- Valuation CSPC Pharmaceutical Group Limited
Select your edition
All financial news and data tailored to specific country editions
















